- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT04898634
Badanie JNJ-78278343, czynnika przekierowującego limfocyty T celującego w ludzką kalikreinę 2 (KLK2), w przypadku zaawansowanego raka prostaty
Badanie fazy 1 JNJ-78278343, czynnika przekierowującego komórki T ukierunkowanego na ludzką kalikreinę 2 (KLK2), w zaawansowanym raku prostaty
The purpose of this study is to determine the recommended phase 2 dose(s) (RP2Ds) of JNJ-78278343 in Part 1 (Dose Escalation) and the safety at the RP2Ds in Part 2 (Dose Expansion).
Przegląd badań
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Faza 1
Kontakty i lokalizacje
Lokalizacje studiów
-
-
-
Beijing, Chiny, 100191
- Peking University Third Hospital
-
Chongqing, Chiny, 400030
- Chongqing University Cancer Hospital
-
Guangzhou, Chiny, 510710
- Sun Yat Sen University Cancer Center
-
Wenzhou, Chiny, 325399
- First Affiliated Hospital Of Wenzhou Medical College
-
-
-
-
-
Lyon, Francja, 69373
- Centre Leon Berard
-
Marseille, Francja, 13005
- APHM Hopital Timone
-
Villejuif, Francja, 94800
- Institut Gustave Roussy
-
-
-
-
-
Madrid, Hiszpania, 28040
- Hosp Univ Fund Jimenez Diaz
-
Madrid, Hiszpania, 28050
- Hosp Univ Hm Sanchinarro
-
Málaga, Hiszpania, 29010
- Hosp Virgen de La Victoria
-
-
-
-
-
Amsterdam, Holandia, 1066 CX
- Antoni van Leeuwenhoek
-
Rotterdam, Holandia, 3015 GD
- Erasmus MC
-
-
-
-
-
Kashiwa, Japonia, 277 8577
- National Cancer Center Hospital East
-
Yokohama, Japonia, 232 0024
- Yokohama City University Medical Center
-
-
-
-
New York
-
New York, New York, Stany Zjednoczone, 10065
- Memorial Sloan Kettering Cancer Center
-
New York, New York, Stany Zjednoczone, 10032
- Columbia University Medical Center Herbert Irving Pavilion
-
-
Washington
-
Seattle, Washington, Stany Zjednoczone, 98195-9472
- University of Washington
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Confirmed adenocarcinoma of the prostate which has spread to other body parts
- Part 1: Prior treatment with at least 1 prior novel androgen receptor (AR)-targeted therapy or chemotherapy
- Measurable or evaluable disease
- Concurrent use of any other anticancer treatment must be discontinued for at least 2 weeks before the first dose of study drug
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Prior surgical removal of testicles; or, for participants who have not undergone surgical removal of testicles, must be receiving ongoing androgen deprivation therapy (ADT) with a gonadotropin releasing hormone analog
Exclusion Criteria:
Disease conditions
- Active central nervous system (CNS) involvement
- Toxicity related to prior anticancer therapy has not adequately recovered
Prior/Concomitant Therapy
- Prior treatment with human kallikrein (KLK) 2-targeted therapy
- Received, or are receiving, medications that suppress the immune system within 3 days prior to the first dose of study drug
- Received or plans to receive any live, attenuated vaccine within 4 weeks prior to the first dose of study drug
Prior/Concurrent Medical Conditions
- Diagnosis of cancer other than prostate cancer within 2 years prior to the first dose of study drug
- Solid organ or bone marrow transplantation
- Major clotting diseases within one month prior to the first dose of study drug
- Active autoimmune disease within 12 months prior to the first dose of study drug
- Active infection
- Major diseases of heart and blood vessels within 6 months prior to the first dose of study drug
- Clinically significant lung diseases
- Active or chronic hepatitis B or hepatitis C infection
- Known positive test result for human immunodeficiency virus (unless stable on antiretroviral therapy with undetectable viral load)
- Any serious underlying medical conditions or other issue that would impair the ability of the participant to receive or tolerate the planned treatment
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Nie dotyczy
- Model interwencyjny: Zadanie sekwencyjne
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: JNJ-78278343
Participants will receive JNJ-78278343. The dose levels will be escalated based on the dose limiting toxicities (DLT) evaluation by the study evaluation team (SET) in Part 1 (dose escalation). In Part 2 (dose expansion), participants will receive JNJ-78278343 at recommended phase 2 dose (RP2D) as determined in Part 1. Participants who are still on study treatment (i.e., who are in Treatment Phase) at the time of the long term extension (LTE) will continue to receive study treatment until they reach a reason for discontinuation of treatment or until further notification by the sponsor of a different means for continued supply of study treatment, whichever occurs first. |
JNJ-78278343 will be administered. |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Part 1 and 2: Number of Participants With Adverse Events (AEs)
Ramy czasowe: Up to 1 year and 10 months
|
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study. |
Up to 1 year and 10 months
|
|
Part 1 and 2: Number of Participants With AEs by Severity
Ramy czasowe: Up to 1 year and 10 months
|
Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event. Cytokine release syndrome (CRS) and immune effector cell associated neurotoxicity syndrome (ICANS) will be graded according to the American Society for Transplantation and Cellular Therapy (ASTCT) guidelines. |
Up to 1 year and 10 months
|
|
Part 1: Number of Participants With Dose-Limiting Toxicity (DLT)
Ramy czasowe: Up to 1 year and 10 months
|
Number of participants with DLT will be reported. The DLTs are specific adverse events and are defined as any of the following: high grade non-hematologic toxicity, or hematologic toxicity. |
Up to 1 year and 10 months
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Serum Concentration of JNJ-78278343
Ramy czasowe: Up to 1 year and 10 months
|
Serum concentrations of JNJ-78278343 will be determined. |
Up to 1 year and 10 months
|
|
Systemic Cytokine Concentrations
Ramy czasowe: Up to 1 year and 10 months
|
Cytokine concentrations will be determined for biomarker assessment. |
Up to 1 year and 10 months
|
|
Serum Prostate Specific Antigen (PSA) Concentration
Ramy czasowe: Up to 1 year and 10 months
|
Serum PSA concentration will be measured. |
Up to 1 year and 10 months
|
|
Number of Participants With Anti-JNJ-78278343 Antibodies
Ramy czasowe: Up to 1 year and 10 months
|
Serum samples will be analyzed for the detection of anti-JNJ-78278343 antibodies using a validated assay method. |
Up to 1 year and 10 months
|
|
Objective Response Rate (ORR)
Ramy czasowe: Up to 1 year and 10 months
|
ORR is defined as the percentage of participants who have a partial response (PR) or better according to the response evaluation criteria in solid tumors (RECIST) version 1.1 response criteria without evidence of bone progression according to prostate cancer working group 3 (PCWG3). |
Up to 1 year and 10 months
|
|
Radiographic Progression-free Survival (rPFS)
Ramy czasowe: Up to 1 year and 10 months
|
rPFS is defined as time from the date of first dose of JNJ-78278343 until the date of objective disease progression or death, whichever comes first. |
Up to 1 year and 10 months
|
|
PSA Response Rate
Ramy czasowe: Up to 1 year and 10 months
|
PSA response rate is defined as the percentage of participants with a decline of PSA of 50 percent (%) or more from baseline. The maximum reduction from baseline in PSA will also be calculated during the treatment. |
Up to 1 year and 10 months
|
|
Duration of Response (DOR)
Ramy czasowe: Up to 1 year and 10 months
|
DOR will be calculated among responders (PR or better) from the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease, as defined in the PCWG3 or RECIST version 1.1 response criteria, or death due to any cause, whichever occurs first. |
Up to 1 year and 10 months
|
Współpracownicy i badacze
Śledczy
- Dyrektor Studium: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Publikacje i pomocne linki
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- CR108958
- 2020-005970-83 (Numer EudraCT)
- 78278343PCR1001 (Inny identyfikator: Janssen Research & Development, LLC)
- 2023-506585-31-00 (Identyfikator rejestru: EUCT number)
- 2023 (Grant/umowa NIH USA)
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
produkt wyprodukowany i wyeksportowany z USA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .